http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20110117621-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb0d9a06f4c98fe19ed3db1ae100d48e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 |
| filingDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f13d6ae011109bb43c1be4b4c8768ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c4fac9941bfba080d039721c5022757 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80b3cd343395afa92ae032bbe9562c7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_543b61723802b6d27fb0879552be8229 |
| publicationDate | 2011-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20110117621-A |
| titleOfInvention | Use of Haedes as a Tumor Suppressor Target |
| abstract | The present invention relates to the use of Hades as a tumor suppression target, and more particularly to a composition for inhibiting tumors containing an inhibitor of the expression or action of Hades protein having the amino acid sequence of SEQ ID NO: 2 as an active ingredient. By confirming that overexpressed Hades interacts with p53 and inhibits p53's exonuclear mechanism, it inhibits p53's tumor suppressor function and confirms that knockdown of Hades increases p53 expression. Hades was first identified as a negative regulator of p53. Therefore, inhibition of Hades' overexpression in tumor cells would effectively trigger tumor suppression by p53. In other words, it is possible to develop inhibitors to regulate the expression of Hades protein or to inhibit the action of Hades, as well as to derive new drug candidates that inhibit the interaction between Hades and p53 and to use them as anticancer agents. |
| priorityDate | 2010-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 536.